Advanced Solid Tumours Clinical Trial
Official title:
A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
The aim of part 1 of this study is to determine the optimal biological dose (OBD) and maximum tolerated dose (MTD) for WX-554 and the recommended dose/dose schedules for the chronic treatment in part 2. The aim of part 2 is to further determine the safety and tolerability of chronic treatment with WX-554.
n/a
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05514132 -
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
|
Phase 1 | |
| Terminated |
NCT04949425 -
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT05537051 -
A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT02579226 -
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01668550 -
A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT01058538 -
A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT02588105 -
Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT03852823 -
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
|
Phase 1 | |
| Not yet recruiting |
NCT06380816 -
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01585701 -
Phase I Study of AT13148, a Novel AGC Kinase Inhibitor
|
Phase 1 | |
| Completed |
NCT03101839 -
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
|
Phase 1 | |
| Completed |
NCT03150368 -
Extended Use of ModraDoc006/r
|
Phase 1 | |
| Active, not recruiting |
NCT02389842 -
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
|
Phase 1 | |
| Terminated |
NCT04959266 -
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
|
Phase 1 | |
| Completed |
NCT04462952 -
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
|
Phase 1 | |
| Active, not recruiting |
NCT03518606 -
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
|
Phase 1/Phase 2 | |
| Completed |
NCT02430311 -
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
|
Phase 1 | |
| Terminated |
NCT01859351 -
Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours
|
Phase 1 | |
| Completed |
NCT01163903 -
Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05804526 -
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
|
Phase 1/Phase 2 |